Gemigliptin Tartrate(911637-19-9 free base) NEW
| Price | $34 | $55 | $89 |
| Package | 2mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-04-30 |
Product Details
| Product Name: Gemigliptin Tartrate(911637-19-9 free base) | CAS No.: 1374639-74-3 |
| Purity: 98% | Supply Ability: 10g |
| Release date: 2025/04/30 |
Product Introduction
Bioactivity
| Name | Gemigliptin Tartrate(911637-19-9 free base) |
| Description | Gemigliptin Tartrate (LC15-0444 tartrate) is a highly selective, reversible and competitive inhibitor of dipeptidyl peptidase-4 (DPP-4). It has an IC50 of 10.3 nM for human recombinant DPP-4. Gemigliptin tartrate exhibits potent anti-glycation properties. |
| In vitro | Gemigliptin tartrate inhibits the formation of AGE-BSA with IC50 of 11.69 mM[1]. Gemigliptin tartrate suppresses the cross-linking of preformed AGE-BSA with rat tail tendon collagen with an IC50 of 1.39 mM[1]. Gemigliptin tartrate is a competitive DPP-4 inhibitor with a Ki of 7.25 nM[2]. |
| In vivo | Gemigliptin tartrate inhibits AGEs formation and AGE cross-links in vivo[1]. Gemigliptin tartrate dose-dependently inhibits plasma DPP-4 activity in rats, dogs, and monkeys[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 90 mg/mL (140.75 mM), Sonication is recommended. |
| Keywords | type | products | peptidase-4 | mellitus | LC15-0444 Tartrate | LC15-0444 | Inhibitor | inhibit | glycation | Gemigliptin Tartrate(911637-19-9 free base) | Gemigliptin Tartrate(911637199 free base) | Gemigliptin Tartrate(911637 19 9 free base) | Gemigliptin | end | DPP-4 | DPP4 | DPP | Dipeptidyl Peptidase | dipeptidyl | diabetes | AGE | advanced |
| Inhibitors Related | (R)-MG-132 | Sitagliptin | Teneligliptin hydrobromide | Sitagliptin phosphate monohydrate | Anagliptin | TCH-165 | Linagliptin | Aprotinin | Vildagliptin | Alloxan monohydrate | 4'-Hydroxychalcone | Bortezomib |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compound Library | Approved Drug Library | Ubiquitination Compound Library | Protease Inhibitor Library | Drug Repurposing Compound Library | Inhibitor Library | Metabolism Compound Library | Clinical Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $68.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2025-04-27 | |
| $0.00/1kg |
VIP6Y
|
Zison Pharmaceutical (Shandong) Co., Ltd.
|
2024-05-24 | |
| $102.00/1kg |
VIP2Y
|
Wuhan Quanjinci New Material Co.,Ltd.
|
2023-10-24 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY